TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)
Clinical Cancer Research, 06/08/2012
Cheng LL et al. – The results highlight an important role for TP53 genomic status in influencing DZNep response in gastric cancer (GC). Clinical trials evaluating EZH2–targeting agents such as DZNep should consider stratifying GC patients by their TP53 genomic status.